Deterioration of Respiratory Symptoms in Uncontrolled CPFE: A Case Report
Downloads
Introduction: Chronic obstructive pulmonary disease (COPD) has a global impact on health and increases healthcare costs. CPFE combines ILD and emphysema. Excessive SABA usage escalates exacerbation risk, affecting prognosis.
Case: A 44-year-old former smoker presented with worsening shortness of breath, cough, and weight loss. Examination showed respiratory distress, including wheezing. Initially, he was diagnosed with TB and COPD exacerbation. He regularly used jet nebulizers without medical supervision, and during the initial treatment, he developed acute respiratory failure, leading to acidosis. Treatment involved SABA and SAMA, steroids, and oxygen therapy. In November 2023, his condition worsened, requiring emergency treatment. Radiological findings indicated combined pulmonary fibrosis and emphysema (CPFE). Management included nebulized medications, intravenous steroids, and antibiotics. Despite challenges, he rarely attended follow-up appointments after showing improvement, missing scheduled rehabilitation therapy, inhaler monitoring, comorbid therapy, and home oxygen monitoring.
Conclusion: CPFE combines ILD and emphysema, causing severe respiratory impairment. Management mirrors that of COPD, involving inhalers, corticosteroids, and oxygen therapy.
Wong AW, Liang J, Cottin V, Ryerson CJ. Diagnostic features in combined pulmonary fibrosis and emphysema: a systematic review. Ann Am Thorac Soc. 2020;17:1333–6. [PubMed]
Hage R, Gautschi F, Steinack C, Schuurmans MM. Combined pulmonary fibrosis and emphysema (CPFE): clinical features and management. Int J Chron Obstruct Pulmon Dis. 2021;16:167–77. Dove Medical Press Ltd. [PubMed]
Cottin V, Inoue Y, Selman M, Ryerson CJ, Wells AU, Agusti A, et al. Syndrome of combined pulmonary fibrosis and emphysema: an official ATS/ERS/JRS/ALAT research statement. Am J Respir Crit Care Med. 2022 Aug 15;206(4):E7–41. [PubMed]
Choi JY, Song JW, Rhee CK. Chronic obstructive pulmonary disease combined with interstitial lung disease. Tuberc Respir Dis (Seoul). 2022 Apr 1;85(2):122–36. [PubMed]
Sangani R, Ghio A, Culp S, Patel Z, Sharma S. Combined pulmonary fibrosis emphysema: role of cigarette smoking and pulmonary hypertension in a rural cohort. Int J Chron Obstruct Pulmon Dis. 2021;16:1873–85. [PubMed]
Ni H, Wei Y, Yang L, Wang Q. An increased risk of pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema: a meta-analysis. BMC Pulm Med. 2023 Dec 1;23(1). [PubMed]
Demirdöğen E, Dilektaşlı AG, Öztürk NAA, Yeşilbursa D, Budak F, Öztürk A, et al. Serum Krebs von den Lungen-6: a promising biomarker to differentiate CPFE from IPF. Sarcoidosis Vasc Diffuse Lung Dis. 2022 Dec 1;39(4). [PubMed]
Bédard Méthot D, Leblanc É, Lacasse Y. Meta-analysis of gastroesophageal reflux disease and idiopathic pulmonary fibrosis. Chest. 2019;155(1):33–43. doi:10.1016/j.chest.2018.07.0388 [PubMed]
Wang X, Wright Z, Wang J, Roy S, Fass R, Song G. Elucidating the link: chronic obstructive pulmonary disease and the complex interplay of gastroesophageal reflux disease and reflux-related complications. Medicina (Lithuania). 2023 Jul 1;59(7). [PubMed]
Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of COPD. 2023. Available from: http://goldcopd.org/ [PubMed]
Fu Y, Chapman EJ, Boland AC, Bennett MI. Evidence-based management approaches for patients with severe chronic obstructive pulmonary disease (COPD): a practice review. Palliat Med. 2022;36:770–82. SAGE Publications Ltd. [PubMed]
Janson C, Wiklund F, Telg G, Stratelis G, Sandelowsky H. High use of short-acting β2-agonists in COPD is associated with an increased risk of exacerbations and mortality. ERJ Open Res. 2023 May 1;9(3). [PubMed]
Nwaru BI, Ekström M, Hasvold P, Wiklund F, Telg G, Janson C. Overuse of short-acting β2-agonists in asthma is associated with increased risk of exacerbation and mortality: a nationwide cohort study of the global SABINA programme. Eur Respir J. 2020 Apr 1;55(4). [PubMed]
Ellis AK, Foran V, Kaplan A, et al. Clarifying SABA overuse: translating Canadian Thoracic Society guidelines into clinical practice. Allergy Asthma Clin Immunol. 2022;18:48. doi:10.1186/s13223-022-00690-2 [PubMed]
Maltais F, Naya IP, Vogelmeier CF, et al. Salbutamol use in relation to maintenance bronchodilator efficacy in COPD: a prospective subgroup analysis of the EMAX trial. Respir Res. 2020;21:280. [PubMed]
López-Campos JL, Gallego EQ, Hernández LC. Status of and strategies for improving adherence to COPD treatment. Int J Chron Obstruct Pulmon Dis. 2019;14:1503–15. Dove Medical Press Ltd. [PubMed]
Sandelowsky H, Weinreich UM, Aarli BB, Sundh J, Høines K, Stratelis G, et al. COPD – do the right thing. BMC Fam Pract. 2021;22. [PubMed]
Sculley JA, Corbridge SJ, Prieto-Centurion V, Kallstrom TJ, Lewarski J, Tan AYM, et al. Home oxygen therapy for patients with COPD: time for a reboot. Respir Care. 2019 Dec 1;64(12):1574–85. [PubMed]
Jacobs SS, Krishnan JA, Lederer DJ, Ghazipura M, Hossain T, Tan AYM, et al. Home oxygen therapy for adults with chronic lung disease: an official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med. 2020 Nov 15;202(10):21–41. [PubMed]
McDonald CF. Home oxygen therapy. Aust Prescr. 2022 Feb 1;45(1):21–4. [Journal]
Cottin V, Azuma A, Raghu G, et al. Therapeutic effects of nintedanib are not influenced by emphysema in the INPULSIS trials. Eur Respir J. 2019;53(4). doi:10.1183/13993003.01655-2018 [PubMed]
Jacobs SS, Krishnan JA, Lederer DJ, et al. Home oxygen therapy for adults with chronic lung disease: an official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med. 2020;202:e121–e141. [PubMed: 33185464]
Copyright (c) 2025 Frans Raffael, Amira Permatasari Tarigan
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
1. The journal allows the author to hold the copyright of the article without restrictions.
2. The journal allows the author(s) to retain publishing rights without restrictions.
3. The legal formal aspect of journal publication accessibility refers to Creative Commons Attribution Share-Alike (CC BY-SA).
4. The Creative Commons Attribution Share-Alike (CC BY-SA) license allows re-distribution and re-use of a licensed work on the conditions that the creator is appropriately credited and that any derivative work is made available under "the same, similar or a compatible license”. Other than the conditions mentioned above, the editorial board is not responsible for copyright violation.
JR (